CAMBRIDGE, Mass.--(BUSINESS WIRE)--Orbital Therapeutics, a company focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease, today announced the appointment of Ron Philip as chief executive officer (CEO) and a member of its board of directors. Mr. Philip brings to Orbital more than 30 years of biopharma leadership experience, including most recently as CEO of Spark Therapeutics, a member of the Roche Group.

马萨诸塞州剑桥市——（商业新闻短讯）——轨道治疗公司（Orbital Therapeutics）今天宣布任命罗恩·菲利普（Ron Philip）为首席执行官（CEO）及其董事会成员，该公司专注于通过释放RNA药物治疗人类疾病的全部潜力来增强全球健康。菲利普先生为Orbital带来了30多年的生物制药领导经验，包括最近担任罗氏集团成员Spark Therapeutics首席执行官。

Mr. Philip succeeds founding CEO Giuseppe “Pino” Ciaramella, Ph.D., who will remain a scientific and strategic advisor to Orbital. Dr. Ciaramella is president of Beam Therapeutics, a strategic partner to Orbital..

Philip先生接替创始人首席执行官Giuseppe“Pino”Ciaramella博士，后者将继续担任Orbital的科学和战略顾问。Ciaramella博士是Orbital的战略合作伙伴Beam Therapeutics的总裁。。

“Alongside my esteemed co-founders, we created Orbital to expand the applicability of RNA-based medicines across a range of human diseases, a pursuit that I am particularly passionate about. It has been a tremendous privilege to build this incredible company and team,” said Dr. Ciaramella. “Having made significant progress across our scientific platform and programs, now is the time to hand the reins to a full-time leader.

“与我尊敬的联合创始人一起，我们创建了Orbital，以扩大基于RNA的药物在一系列人类疾病中的适用性，这是我特别热衷的追求。建立这家令人难以置信的公司和团队是我莫大的荣幸，”Ciaramella博士说。“在我们的科学平台和项目上取得了重大进展，现在是时候把控制权交给全职领导者了。

Ron’s track record in biopharma leadership, deep experience in genetic medicines, and expertise in scaling emerging organizations make him the perfect fit to lead Orbital at this critical juncture. I look forward to continuing to be a part of Orbital’s legacy as a strategic advisor and supporting Ron in his new role.”.

罗恩在生物制药领域的领导记录、在基因药物领域的丰富经验以及在扩展新兴组织方面的专业知识，使他非常适合在这个关键时刻领导轨道公司。作为战略顾问，我期待着继续成为轨道公司遗产的一部分，并支持罗恩担任新角色。”。

“Orbital’s mission to enhance global health by unleashing the full potential of RNA medicines is both inspiring and essential, and I am thrilled to join such an ambitious and talented company,” said Mr. Philip. “Over the course of my career, I’ve pursued opportunities that have pushed the boundaries of science to bring new therapies to patients.

菲利普先生说：“轨道公司通过释放RNA药物的全部潜力来增强全球健康的使命既鼓舞人心又至关重要，我很高兴加入这样一家雄心勃勃且才华横溢的公司。”。“在我的职业生涯中，我一直在寻求突破科学界限的机会，为患者带来新的治疗方法。

I firmly believe that Orbital’s state-of-the-art platform has the potential to expand the possibilities of RNA-based treatments, with RNA programs that precisely align with the distinct attributes needed to treat a specific disease. The incredible work Pino and the team have accomplished in building Orbital’s capabilities and advancing its diverse portfolio sets a strong foundation for, what I believe, will be a transformative future for the field of genetic medicine.”.

我坚信，Orbital最先进的平台有可能扩大基于RNA的治疗的可能性，RNA程序与治疗特定疾病所需的独特属性精确一致。皮诺和团队在构建轨道的能力和推进其多样化投资组合方面所完成的令人难以置信的工作为我相信的遗传医学领域的变革性未来奠定了坚实的基础。”。

Mr. Philip is a proven leader with extensive experience in building companies, leading organizational growth, and guiding teams through the development of therapies for people living with genetic diseases. During his time at Spark Therapeutics, he led the company through the commercial launch of the first approved gene therapy for a genetic disease, LUXTURNA® (voretigene neparvovec-rzyl); led the transition and growth of the company from founder-led to a fully integrated standalone business as part of the Roche Group; pivoted Spark’s platform to target larger disease areas; acquired technologies and therapeutic assets through business development efforts; and oversaw the initiation and build of a state-of-the-art 600,000 sq.

菲利普先生是一位久经考验的领导者，在建立公司、领导组织发展以及指导团队开发针对遗传病患者的疗法方面拥有丰富经验。在Spark Therapeutics任职期间，他领导该公司商业推出了首个经批准的遗传疾病基因疗法LUXTURNA®（voretigene neparvovec rzyl）；作为罗氏集团的一部分，领导公司从创始人转变为完全整合的独立业务；pivoted Spark的平台针对更大的疾病领域；通过业务发展努力获得技术和治疗资产；并监督了60万平方米最先进建筑的启动和建设。

ft. Gene Therapy Innovation Center that will open in 2026. Before joining Spark, Mr. Philip spent a decade at Pfizer and Wyeth, where he held several senior leadership roles, including regional president for Africa/Middle East, head of global business unit strategy, head of business development search and evaluation, and commercial development lead within Pfizer’s innovative products business.

基因治疗创新中心将于2026年开放。在加入Spark之前，Philip先生在辉瑞和惠氏工作了十年，担任过多个高级领导职务，包括非洲/中东地区总裁、全球业务部门战略负责人、业务发展搜索和评估负责人，以及辉瑞创新产品业务中的商业发展负责人。

Earlier, he worked at Deloitte Consulting in the strategy and operations practice and at Merck & Co. in the company’s manufacturing and marketing divisions. Mr. Philip currently serves as a board member at the Academy of Natural Sciences of Drexel University in Philadelphia, at the Chamber of Commerce for Greater Philadelphia, at Life Sciences Pennsylvania and was previously an active board member of Cure Duchenne.

此前，他曾在德勤咨询（Deloitte Consulting）从事战略与运营实践，并在默克公司（Merck&Co.）的制造和营销部门工作。Philip先生目前担任费城德雷克塞尔大学自然科学院、宾夕法尼亚州生命科学学院大费城商会的董事会成员，此前是Cure Duchenne的董事会活跃成员。

He is a graduate of Drexel University..

他毕业于德雷克塞尔大学。。

About Orbital Therapeutics

关于眼眶治疗学

Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. The company is leveraging its first-in-kind platform at the intersection of RNA technology, delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of immunomodulation for autoimmune disease and oncology, next-generation vaccines, and protein therapeutics.

Orbital Therapeutics旨在通过释放基于RNA的药物以以前不可能的方式治疗人类疾病的全部潜力来增强全球健康。该公司正在利用其在RNA技术，传递方法，数据科学和自动化交叉点的第一个实物平台来开发广泛的药物组合，最初专注于自身免疫疾病和肿瘤学的免疫调节领域，下一代疫苗和蛋白质治疗。

Founded by experts in the fields of genetic medicine and RNA development and delivery, Orbital has an operational structure designed to harness the ingenuity of a deep and diverse team of scientists, drug developers and business leaders. For more information, please visit www.OrbitalTx.com..

Orbital由遗传医学和RNA开发与传递领域的专家创建，其运营结构旨在利用由科学家、药物开发人员和商业领袖组成的深度多样团队的创造力。有关更多信息，请访问www.OrbitalTx.com。。